Arkolith/Insider Trading/VTGN/Form 4

Singh Shawn

CHIEF EXECUTIVE OFFICER, DirectorVistagen Therapeutics, Inc. (VTGN) · full profile →Form 4 · filed Jan 3, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 29, 2023Grant(A)167$1.72$2876K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-000344) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML